PTHS SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2026

10-Q/A

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Aug 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 19, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Pelthos Therapeutics Enters Merger Agreement with Castle Creek Biosciences and $57.5 Million PIPE Financing

Oct 30, 2026

8-K

Pelthos Therapeutics Announces Voting Results from 2026 Annual Meeting and Approval of New Equity Incentive Plan

Oct 1, 2026

8-K

Pelthos Therapeutics Announces Second Quarter 2026 Financial Results

Aug 13, 2026

8-K

Pelthos Therapeutics Inc. Announces Restatement of Financial Statements for Q1 2026

Aug 13, 2026

8-K

Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

May 28, 2026

8-K

Pelthos Therapeutics Inc. Announces Auditor Change and Separation Agreement with Former CFO

May 21, 2026

Prospectus

TYPE

HEADLINE

FILED AT

425

Form 425 - Prospectuses and communications, business combinations

Oct 30, 2026

425

Form 425 - Prospectuses and communications, business combinations

Oct 30, 2026

424B3

SHARE RESALE REGISTRATION | Shares: 781,928

Feb 13, 2026

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 8,137,868 |

Sep 29, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 2,969,823

Nov 13, 2024

424B3

UPDATED | OFFERING | Shares amount: 1,155,000 | Warrants amount: 55,000

Nov 13, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-3

February 2026 SHELF | SHARE RESALE REGISTRATION

Feb 2, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Nov 18, 2025

S-3/A

SHARE RESALE REGISTRATION

Sep 19, 2025

S-3

SHARE RESALE REGISTRATION

Aug 28, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 25, 2025

Form D - Notice of Exempt Offering of Securities - Item 06b

Jul 10, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Aug 18, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Aug 18, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Aug 7, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Nov 25, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Nov 14, 2025

DEFM14C

Form DEFM14C - Definitive information statement relating to merger or acquisition

May 27, 2025

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13D/A

LIGAND PHARMACEUTICALS INC (Filed by)

Nov 3, 2026

Greenleaf Peter (Reporting)

Oct 6, 2026

Friedberg Ezra M (Reporting)

Oct 6, 2026

Pauls Matthew (Reporting)

Oct 6, 2026

Friedberg Ezra M (Reporting)

Jul 7, 2026

Pauls Matthew (Reporting)

Jul 7, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 10, 2026

CORRESP

Form CORRESP - Correspondence

Feb 9, 2026

LETTER

Form UPLOAD - SEC-generated letter

Feb 9, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 25, 2025

CORRESP

Form CORRESP - Correspondence

Sep 24, 2025

CORRESP

Form CORRESP - Correspondence

Sep 19, 2025

Pelthos Therapeutics Inc. PTHS · SEC Filings